471 findings · Metabolic adaptation · published 2022+
- Metabolic adaptationStrong
Sustained significant weight loss through lifestyle changes is difficult for people with obesity in the long term.
Practitioners should be aware of the challenges faced by patients in achieving long-term weight loss.
Supports 2023 - Metabolic adaptationStrong
HEC-CG115 led to more weight loss than semaglutide in diet-induced obese model mice.
HEC-CG115 may be a more effective option for weight loss in obese patients compared to semaglutide.
Supports 2023 - Metabolic adaptationStrong
Gastric bypass patients had an 85% lower risk of developing type 2 diabetes compared to non-operated patients with obesity during the first six years of follow-up.
Gastric bypass surgery significantly reduces the risk of type 2 diabetes in obese patients, especially in the first six years post-surgery.
Supports 2024 - Metabolic adaptationStrong
There is a strong imperative to assess the health effects of sugar-sweetened beverages as the burden of noncommunicable diseases increases.
Increased research on sugar-sweetened beverages is necessary to inform public health policies.
Supports 2022 - Metabolic adaptationStrong
Physical frailty and sarcopenia are associated with morbidity and 2-fold mortality in patients with advanced chronic liver disease awaiting liver transplantation.
Healthcare providers should assess frailty and sarcopenia in liver transplant candidates to improve outcomes.
Supports 2025New - Metabolic adaptationStrong
Loss of muscle-related indices exceeded prespecified benchmarks in two thirds of incretin-based interventions.
Clinicians should monitor muscle mass when prescribing incretin therapies for weight loss.
Supports 2026New - Metabolic adaptationStrong
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for diastolic dysfunction and heart failure with preserved ejection fraction (HFpEF), increasing the risk of hospitalization and death in those with established heart failure.
Clinicians should consider screening for MASLD in patients with HFpEF due to the increased risk of adverse outcomes.
Supports 2024 - Metabolic adaptationStrong
Heart failure with preserved ejection fraction (HFpEF) exacerbates the severity of metabolic dysfunction-associated steatotic liver disease (MASLD).
Healthcare providers should be aware that HFpEF can worsen MASLD, necessitating comprehensive management strategies.
Supports 2024 - Metabolic adaptationStrong
BMI is not sufficient to define obesity; pathophysiology and the impact of mechanical, metabolic, and psychological complications must be considered.
Practitioners should consider multiple factors beyond BMI when assessing obesity.
Supports 2025New - Metabolic adaptationStrong
There was no difference between the intervention periods regarding mean blood glucose (MBG), time in range (TIR), and hypoglycemic events.
GTSS does not negatively impact overall glucose control or increase hypoglycemic risk.
Supports 2022 - Metabolic adaptationStrong
Up to 33% of the weight lost on GLP-1 RAs may be lean tissue mass.
Practitioners should monitor body composition changes in patients using GLP-1 RAs.
Qualifies 2026New - Metabolic adaptationStrong
GLP-1RAs may raise safety concerns related to weight loss and altered glucose regulation in ALS.
Monitoring for weight loss and glucose regulation is essential when considering GLP-1RAs for ALS.
Qualifies 2026New - Metabolic adaptationStrong
Excess visceral abdominal fat (EVAF) can occur in people living with HIV-1 even with normal or mildly elevated body mass index (BMI).
Healthcare providers should assess visceral fat in PLWH regardless of BMI.
Supports 2026New - Metabolic adaptationStrong
Hemoglobin A1c decreased across all groups but remained consistently higher in NHB and H compared with NHW at 24 months.
Monitoring of Hemoglobin A1c levels should be tailored based on race and ethnicity post-surgery.
Supports 2025New - Metabolic adaptationStrong
Perturbations in cardiac energy metabolism are a major contributor to diabetes-related cardiovascular disease.
Addressing cardiac energy metabolism may be crucial in managing cardiovascular disease in T2D patients.
Supports 2024 - Metabolic adaptationStrong
Non-responders to the PF regimen demonstrated only transient and limited metabolic shifts.
Understanding the differences in metabolic responses can guide dietary strategies for T2D management.
Supports 2025New - Metabolic adaptationStrong
A shift towards reduced carbohydrate intake and increased dietary fat may be linked to higher morbidity and mortality rates in patients with diabetes.
Practitioners should consider the implications of dietary fat and carbohydrate ratios in diabetes management.
Supports 2025New - Metabolic adaptationStrong
The majority of animal studies demonstrated a greater impact from high-fat diets compared with higher-sugar diets.
Animal studies suggest that high-fat diets may pose greater risks than high-sugar diets, informing dietary recommendations.
Supports 2025New - Metabolic adaptationStrong
A plant-based diet is associated with an increased risk of higher TyG in women (OR = 1.25 for PDI and OR = 1.55 for hPDI).
Practitioners should be cautious about recommending high plant-based diets for women without considering overall dietary balance.
Supports 2025New - Metabolic adaptationStrong
Physiological adaptation from a low- to high-carbohydrate diet may require many weeks.
Practitioners should consider that dietary transitions may not yield immediate metabolic changes.
Supports 2022 - Metabolic adaptationStrong
Physiological adaptation from a low- to high-carbohydrate diet may require many weeks.
Practitioners should consider the time required for metabolic adaptation when advising dietary transitions.
Supports 2022 - Metabolic adaptationStrong
Over 700 million people worldwide suffer from obesity, which is directly or indirectly responsible for about 7% of all deaths.
Healthcare practitioners should recognize the widespread impact of obesity on public health.
Supports 2023 - Metabolic adaptationStrong
Bariatric surgery is recommended for the treatment of type 2 diabetes in extreme cases.
Consider bariatric surgery for patients with severe diabetes who do not respond to other treatments.
Supports 2023 - Metabolic adaptationStrong
Metabolic dysfunction-associated steatotic liver disease (MASLD) is very common in individuals with type 2 diabetes.
Healthcare providers should be aware of the high prevalence of MASLD in their diabetic patients.
Supports 2026New